Every recall we track for The Harvard Drug Group — 45 in all — plus the complaints and injury reports the public filed about them.
Harvard Drug Group recalls 600mg Gabapentin tablets (NDC 0904-6823-61) after finding a foreign tablet in some products. This recall is for prescription-only items sold between specific dates.
The Harvard Drug Group recalls Carbidopa and Levodopa tablets due to blister packaging that may not seal properly. This could lead to medication exposure risks for patients using prescription medication.
Harvard Drug Group recalls 9mg paliperidone extended-release tablets with failed dissolution specs. Affected units have NDC 0904-6937-61 and specific lot numbers. Consumers should contact for remedy.
The Harvard Drug Group recalls 10 mg hydrALAZINE HCl tablets due to impurities found in stability testing. This affects specific lots from March 2023. No remedy is stated in the recall notice.
The Harvard Drug Group recalls Carbamazepine 200mg tablets due to failed dissolution specifications. This may affect medication effectiveness. Check your product details to see if you are affected.
Harvard Drug Group recalls 60mg fexofenadine tablets with impurities that could pose health risks. Affected lots expired by April 2022. Consumers should check NDC 0904-6979-40 and lot numbers.
Harvard Drug Group recalls 30mg Nifedipine extended-release tablets (NDC 0904-7080-61 and 0904-7080-06) due to failed dissolution testing. These prescription-only medications may not release properly in the body.